| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 23 | 2021 | 690 | 6.290 |
Why?
|
| Drainage | 14 | 2021 | 416 | 4.590 |
Why?
|
| Pancreatectomy | 20 | 2023 | 652 | 4.010 |
Why?
|
| Pancreatic Neoplasms | 77 | 2023 | 5061 | 3.580 |
Why?
|
| Postoperative Complications | 20 | 2021 | 5542 | 2.010 |
Why?
|
| Pancreatic Fistula | 8 | 2021 | 99 | 1.890 |
Why?
|
| Receptors, Somatostatin | 14 | 2011 | 85 | 1.860 |
Why?
|
| Postoperative Care | 5 | 2019 | 739 | 1.830 |
Why?
|
| Pancreatitis, Chronic | 6 | 2023 | 116 | 1.670 |
Why?
|
| Carcinoma, Pancreatic Ductal | 14 | 2023 | 1724 | 1.340 |
Why?
|
| Pancreatic Diseases | 5 | 2021 | 108 | 1.180 |
Why?
|
| Pancreatic Cyst | 3 | 2021 | 107 | 0.980 |
Why?
|
| Amylases | 4 | 2019 | 66 | 0.930 |
Why?
|
| Carotenoids | 1 | 2022 | 96 | 0.820 |
Why?
|
| Adenocarcinoma | 25 | 2023 | 7789 | 0.790 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 1999 | 224 | 0.680 |
Why?
|
| Device Removal | 2 | 2018 | 337 | 0.670 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 25 | 0.650 |
Why?
|
| Somatostatin | 6 | 2011 | 114 | 0.620 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 73 | 0.620 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 117 | 0.590 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 384 | 0.560 |
Why?
|
| Quality Indicators, Health Care | 3 | 2016 | 348 | 0.540 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.530 |
Why?
|
| Humans | 133 | 2023 | 261506 | 0.510 |
Why?
|
| Learning Curve | 2 | 2013 | 68 | 0.510 |
Why?
|
| Insulin | 9 | 2011 | 1454 | 0.460 |
Why?
|
| Bile | 1 | 2013 | 81 | 0.460 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 45 | 0.460 |
Why?
|
| Male | 70 | 2021 | 123000 | 0.450 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.450 |
Why?
|
| Treatment Outcome | 24 | 2019 | 32848 | 0.430 |
Why?
|
| Pancreas | 9 | 2023 | 718 | 0.430 |
Why?
|
| Decompression | 1 | 2011 | 12 | 0.410 |
Why?
|
| Unnecessary Procedures | 2 | 2011 | 104 | 0.400 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 212 | 0.400 |
Why?
|
| Gastroenterology | 1 | 2014 | 195 | 0.400 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 79 | 0.390 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 43 | 0.390 |
Why?
|
| Genetic Therapy | 8 | 2011 | 1616 | 0.380 |
Why?
|
| Female | 55 | 2022 | 141928 | 0.370 |
Why?
|
| Surgical Wound Infection | 2 | 2013 | 450 | 0.370 |
Why?
|
| Middle Aged | 41 | 2022 | 86204 | 0.370 |
Why?
|
| Precision Medicine | 3 | 2014 | 1154 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.360 |
Why?
|
| Aged | 34 | 2021 | 70117 | 0.360 |
Why?
|
| Neurilemmoma | 1 | 2010 | 127 | 0.350 |
Why?
|
| Cation Transport Proteins | 4 | 2013 | 199 | 0.350 |
Why?
|
| Risk Factors | 16 | 2021 | 17523 | 0.350 |
Why?
|
| Tissue Banks | 1 | 2009 | 55 | 0.340 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2018 | 1146 | 0.330 |
Why?
|
| Time Factors | 13 | 2021 | 12926 | 0.320 |
Why?
|
| Laparoscopy | 6 | 2017 | 1225 | 0.320 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 51 | 0.310 |
Why?
|
| Cell Proliferation | 17 | 2018 | 7226 | 0.310 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 1058 | 0.300 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 4892 | 0.300 |
Why?
|
| Pancreatitis | 3 | 2020 | 267 | 0.300 |
Why?
|
| Thymosin | 4 | 2009 | 29 | 0.300 |
Why?
|
| Gastrointestinal Hormones | 2 | 1998 | 26 | 0.300 |
Why?
|
| Antigens, Neoplasm | 5 | 2018 | 1506 | 0.300 |
Why?
|
| Proteins | 3 | 2021 | 1963 | 0.290 |
Why?
|
| Prospective Studies | 10 | 2021 | 12873 | 0.290 |
Why?
|
| Tumor Cells, Cultured | 15 | 2009 | 5395 | 0.270 |
Why?
|
| Journalism, Medical | 1 | 2005 | 11 | 0.270 |
Why?
|
| Homeodomain Proteins | 8 | 2012 | 1143 | 0.270 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 335 | 0.270 |
Why?
|
| Cell Line, Tumor | 27 | 2018 | 14551 | 0.270 |
Why?
|
| Medical Oncology | 1 | 2014 | 1423 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2009 | 3639 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 3 | 2014 | 2330 | 0.260 |
Why?
|
| Peritoneal Cavity | 2 | 2018 | 56 | 0.260 |
Why?
|
| Cell Cycle | 3 | 2014 | 2084 | 0.250 |
Why?
|
| Trans-Activators | 8 | 2012 | 1555 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2018 | 15862 | 0.250 |
Why?
|
| Writing | 1 | 2005 | 104 | 0.240 |
Why?
|
| Factor Xa Inhibitors | 2 | 2018 | 70 | 0.240 |
Why?
|
| Length of Stay | 4 | 2018 | 1900 | 0.240 |
Why?
|
| Specimen Handling | 2 | 2021 | 299 | 0.240 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2018 | 76 | 0.240 |
Why?
|
| Insulin Infusion Systems | 2 | 2005 | 53 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2018 | 7551 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 4 | 2009 | 1547 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2018 | 8873 | 0.230 |
Why?
|
| Clinical Competence | 1 | 2011 | 1270 | 0.230 |
Why?
|
| Retrospective Studies | 17 | 2021 | 37905 | 0.230 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 309 | 0.230 |
Why?
|
| Thymidine Kinase | 3 | 2011 | 193 | 0.220 |
Why?
|
| Survival Analysis | 7 | 2018 | 9180 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 2 | 2018 | 383 | 0.220 |
Why?
|
| Risk Assessment | 8 | 2021 | 6869 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 2594 | 0.220 |
Why?
|
| alpha-Tocopherol | 1 | 2022 | 78 | 0.220 |
Why?
|
| Cholelithiasis | 1 | 2002 | 43 | 0.220 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2002 | 31 | 0.210 |
Why?
|
| Enoxaparin | 2 | 2014 | 66 | 0.210 |
Why?
|
| Zinc | 2 | 2013 | 188 | 0.210 |
Why?
|
| Micronutrients | 1 | 2022 | 75 | 0.210 |
Why?
|
| Duodenal Obstruction | 1 | 2001 | 8 | 0.210 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 14889 | 0.210 |
Why?
|
| Situs Inversus | 1 | 2001 | 27 | 0.210 |
Why?
|
| Anus Diseases | 1 | 2002 | 29 | 0.210 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 70 | 0.210 |
Why?
|
| Octreotide | 3 | 2003 | 118 | 0.210 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 3230 | 0.210 |
Why?
|
| Mice, Nude | 12 | 2018 | 4307 | 0.200 |
Why?
|
| Quality of Life | 4 | 2023 | 4532 | 0.200 |
Why?
|
| Pancreatic Function Tests | 1 | 2021 | 3 | 0.200 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2021 | 84 | 0.200 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2021 | 31 | 0.200 |
Why?
|
| Transfection | 7 | 2010 | 2944 | 0.200 |
Why?
|
| Pancreatic Juice | 1 | 2021 | 13 | 0.200 |
Why?
|
| Gene Expression | 3 | 2017 | 3570 | 0.190 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 2216 | 0.190 |
Why?
|
| Cell Division | 7 | 2007 | 2489 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.190 |
Why?
|
| Nucleic Acids | 1 | 2021 | 43 | 0.190 |
Why?
|
| Adult | 29 | 2021 | 77950 | 0.190 |
Why?
|
| Abscess | 1 | 2002 | 177 | 0.190 |
Why?
|
| Animals | 39 | 2018 | 59536 | 0.190 |
Why?
|
| Interleukin-4 | 2 | 2018 | 284 | 0.190 |
Why?
|
| Biomedical Research | 3 | 2017 | 806 | 0.190 |
Why?
|
| Anastomosis, Surgical | 2 | 2021 | 371 | 0.180 |
Why?
|
| Nutritional Status | 2 | 2019 | 337 | 0.180 |
Why?
|
| Intestinal Fistula | 1 | 2000 | 44 | 0.180 |
Why?
|
| Folic Acid | 1 | 2022 | 349 | 0.180 |
Why?
|
| Cutaneous Fistula | 1 | 2000 | 46 | 0.180 |
Why?
|
| Neoplasm Transplantation | 8 | 2010 | 1519 | 0.180 |
Why?
|
| Duodenal Ulcer | 1 | 2000 | 113 | 0.180 |
Why?
|
| Up-Regulation | 7 | 2013 | 2450 | 0.180 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1999 | 51 | 0.180 |
Why?
|
| Receptor, Insulin | 2 | 1998 | 97 | 0.180 |
Why?
|
| Mental Health Services | 2 | 2012 | 227 | 0.170 |
Why?
|
| Osteoporosis | 1 | 2021 | 241 | 0.170 |
Why?
|
| GPI-Linked Proteins | 5 | 2018 | 223 | 0.170 |
Why?
|
| Amyloidosis | 1 | 2021 | 176 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 436 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 1538 | 0.170 |
Why?
|
| Relative Value Scales | 1 | 2018 | 14 | 0.170 |
Why?
|
| Employee Performance Appraisal | 1 | 2018 | 21 | 0.160 |
Why?
|
| Choristoma | 1 | 2018 | 85 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2018 | 45 | 0.160 |
Why?
|
| RNAi Therapeutics | 1 | 2018 | 42 | 0.160 |
Why?
|
| Mesocricetus | 5 | 1999 | 114 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2011 | 1299 | 0.160 |
Why?
|
| Efficiency | 1 | 2018 | 99 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1038 | 0.160 |
Why?
|
| Mice | 25 | 2018 | 34495 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 51 | 0.150 |
Why?
|
| Rivaroxaban | 1 | 2018 | 59 | 0.150 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2009 | 301 | 0.150 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2001 | 384 | 0.150 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 3869 | 0.150 |
Why?
|
| Neoplasm Staging | 6 | 2017 | 13658 | 0.150 |
Why?
|
| Incidence | 5 | 2019 | 5673 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 2326 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2018 | 218 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 2 | 2018 | 1130 | 0.150 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.150 |
Why?
|
| Cricetinae | 5 | 1999 | 706 | 0.150 |
Why?
|
| Intestines | 1 | 2001 | 686 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2018 | 272 | 0.150 |
Why?
|
| Transplantation, Heterologous | 5 | 2008 | 1082 | 0.150 |
Why?
|
| Semaphorins | 1 | 2016 | 38 | 0.150 |
Why?
|
| Islets of Langerhans | 5 | 2011 | 229 | 0.150 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.150 |
Why?
|
| Cytokines | 5 | 2017 | 2809 | 0.150 |
Why?
|
| RNA, Messenger | 8 | 2008 | 6150 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 4 | 2012 | 2483 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 137 | 0.140 |
Why?
|
| Nutritional Support | 1 | 2017 | 80 | 0.140 |
Why?
|
| Genomics | 4 | 2011 | 2738 | 0.140 |
Why?
|
| Reoperation | 2 | 2018 | 1382 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2018 | 288 | 0.140 |
Why?
|
| Spleen | 1 | 2018 | 676 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2007 | 142 | 0.140 |
Why?
|
| Registries | 3 | 2019 | 2170 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 467 | 0.140 |
Why?
|
| Patient Selection | 3 | 2014 | 2055 | 0.140 |
Why?
|
| Down-Regulation | 5 | 2009 | 2074 | 0.140 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2018 | 383 | 0.140 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 3022 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 108 | 0.140 |
Why?
|
| Cyclophilins | 2 | 2006 | 32 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2018 | 325 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1039 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 1555 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 130 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 96 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2018 | 289 | 0.130 |
Why?
|
| Deoxycytidine | 3 | 2014 | 1353 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 1248 | 0.130 |
Why?
|
| Neuropilins | 2 | 2005 | 14 | 0.130 |
Why?
|
| Motivation | 1 | 2018 | 499 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 138 | 0.130 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2014 | 37 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1362 | 0.130 |
Why?
|
| Gene Expression Profiling | 5 | 2014 | 5159 | 0.130 |
Why?
|
| Human Genome Project | 2 | 2011 | 64 | 0.120 |
Why?
|
| Ganglia, Spinal | 1 | 2016 | 237 | 0.120 |
Why?
|
| Benzylamines | 1 | 2014 | 105 | 0.120 |
Why?
|
| Surgeons | 2 | 2018 | 519 | 0.120 |
Why?
|
| Pancreatic Polypeptide | 2 | 2023 | 17 | 0.120 |
Why?
|
| United States | 8 | 2017 | 15433 | 0.120 |
Why?
|
| MicroRNAs | 3 | 2013 | 2947 | 0.120 |
Why?
|
| Aspirin | 1 | 2018 | 455 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 444 | 0.120 |
Why?
|
| Mental Disorders | 2 | 2012 | 862 | 0.120 |
Why?
|
| Endometriosis | 1 | 2017 | 214 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2018 | 3821 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 752 | 0.120 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2014 | 66 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2018 | 2218 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2018 | 548 | 0.120 |
Why?
|
| Neurogenesis | 1 | 2016 | 238 | 0.120 |
Why?
|
| Mucin-1 | 1 | 2013 | 127 | 0.110 |
Why?
|
| Benzoates | 1 | 2014 | 136 | 0.110 |
Why?
|
| Gastrostomy | 2 | 2006 | 180 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 526 | 0.110 |
Why?
|
| Ganciclovir | 3 | 2011 | 174 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 430 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2008 | 1533 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 194 | 0.110 |
Why?
|
| Hospitals, High-Volume | 1 | 2013 | 77 | 0.110 |
Why?
|
| Microarray Analysis | 2 | 2014 | 392 | 0.110 |
Why?
|
| Mice, SCID | 6 | 2018 | 1869 | 0.110 |
Why?
|
| Abdomen | 1 | 2014 | 332 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1274 | 0.110 |
Why?
|
| Glutamates | 2 | 2010 | 130 | 0.100 |
Why?
|
| Basigin | 3 | 2006 | 20 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 291 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 907 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 332 | 0.100 |
Why?
|
| Guanine | 2 | 2010 | 151 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 264 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 2359 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 181 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 622 | 0.100 |
Why?
|
| Condylomata Acuminata | 1 | 2011 | 26 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 1073 | 0.100 |
Why?
|
| Abdominal Fat | 1 | 2011 | 21 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2013 | 477 | 0.100 |
Why?
|
| Suction | 1 | 2011 | 104 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2016 | 460 | 0.100 |
Why?
|
| Single-Chain Antibodies | 1 | 2011 | 62 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1996 | 840 | 0.100 |
Why?
|
| Prisoners | 1 | 2011 | 34 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2011 | 4549 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 481 | 0.090 |
Why?
|
| Lung Neoplasms | 6 | 2010 | 11538 | 0.090 |
Why?
|
| Lymphocyte Activation | 4 | 2018 | 1688 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 95 | 0.090 |
Why?
|
| Texas | 2 | 2011 | 6311 | 0.090 |
Why?
|
| Sulfones | 1 | 2010 | 143 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 1763 | 0.090 |
Why?
|
| Survival Rate | 6 | 2017 | 12221 | 0.090 |
Why?
|
| RNA, Neoplasm | 3 | 2009 | 771 | 0.090 |
Why?
|
| Organ Preservation Solutions | 1 | 2009 | 20 | 0.090 |
Why?
|
| Informed Consent | 2 | 2011 | 419 | 0.090 |
Why?
|
| Prevalence | 3 | 2021 | 3260 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1064 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 598 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2013 | 451 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 3203 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 2864 | 0.080 |
Why?
|
| Aged, 80 and over | 8 | 2014 | 29902 | 0.080 |
Why?
|
| Tumor Burden | 4 | 2018 | 1987 | 0.080 |
Why?
|
| Blood Glucose | 4 | 2005 | 1244 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 4938 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2011 | 272 | 0.080 |
Why?
|
| Body Weight | 4 | 1999 | 1293 | 0.080 |
Why?
|
| Cell Survival | 3 | 2018 | 3045 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2011 | 195 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2010 | 314 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 14289 | 0.080 |
Why?
|
| Carcinoma | 2 | 2011 | 2578 | 0.080 |
Why?
|
| Prognosis | 5 | 2023 | 21713 | 0.080 |
Why?
|
| Forecasting | 1 | 2011 | 694 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1323 | 0.080 |
Why?
|
| Pancreaticojejunostomy | 1 | 2008 | 14 | 0.080 |
Why?
|
| Genetic Techniques | 1 | 2009 | 130 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2011 | 2203 | 0.080 |
Why?
|
| Neuropilin-2 | 1 | 2008 | 21 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2018 | 3890 | 0.080 |
Why?
|
| Confidentiality | 1 | 2009 | 127 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 2011 | 442 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2011 | 583 | 0.080 |
Why?
|
| Comorbidity | 2 | 2012 | 2352 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2009 | 176 | 0.080 |
Why?
|
| Medicaid | 1 | 2011 | 279 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2011 | 1391 | 0.080 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 46 | 0.080 |
Why?
|
| DNA Primers | 3 | 2005 | 1399 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2018 | 2588 | 0.080 |
Why?
|
| In Vitro Techniques | 3 | 2007 | 1618 | 0.080 |
Why?
|
| Quality Control | 1 | 2009 | 457 | 0.080 |
Why?
|
| Adenoviridae | 3 | 2011 | 1459 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 8865 | 0.070 |
Why?
|
| Oncogenes | 1 | 2010 | 673 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2009 | 298 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 669 | 0.070 |
Why?
|
| Cell Movement | 4 | 2018 | 2466 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 329 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2018 | 9244 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 1084 | 0.070 |
Why?
|
| Abdominal Pain | 2 | 2017 | 369 | 0.070 |
Why?
|
| Gastroenterostomy | 1 | 2006 | 5 | 0.070 |
Why?
|
| Herpesvirus 2, Human | 1 | 2006 | 24 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 1258 | 0.070 |
Why?
|
| Logistic Models | 2 | 2010 | 3441 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 2967 | 0.070 |
Why?
|
| Jejunostomy | 1 | 2006 | 52 | 0.070 |
Why?
|
| Binding, Competitive | 2 | 1996 | 300 | 0.070 |
Why?
|
| Genotype | 2 | 2011 | 4109 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 611 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2010 | 470 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 1399 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2010 | 489 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 2508 | 0.070 |
Why?
|
| Endosonography | 2 | 2021 | 536 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2005 | 355 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 4744 | 0.070 |
Why?
|
| Databases, Genetic | 1 | 2009 | 745 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2008 | 519 | 0.070 |
Why?
|
| Gastric Bypass | 1 | 2006 | 81 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 860 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 4821 | 0.070 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1999 | 159 | 0.060 |
Why?
|
| Exonucleases | 1 | 2005 | 51 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2004 | 9 | 0.060 |
Why?
|
| Alleles | 1 | 2011 | 2437 | 0.060 |
Why?
|
| Neurons | 1 | 2016 | 2287 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 4975 | 0.060 |
Why?
|
| Exoribonucleases | 1 | 2005 | 42 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2010 | 787 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 278 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2005 | 181 | 0.060 |
Why?
|
| Regeneration | 1 | 2007 | 279 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6207 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 4971 | 0.060 |
Why?
|
| 14-3-3 Proteins | 1 | 2005 | 143 | 0.060 |
Why?
|
| Nervous System | 1 | 2005 | 165 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 154 | 0.060 |
Why?
|
| Cytosine Deaminase | 1 | 2004 | 39 | 0.060 |
Why?
|
| Hypoglycemic Agents | 2 | 2007 | 586 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 10001 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 4320 | 0.060 |
Why?
|
| Apoptosis | 7 | 2016 | 7591 | 0.060 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2009 | 406 | 0.060 |
Why?
|
| Antiviral Agents | 2 | 2011 | 1230 | 0.060 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2004 | 69 | 0.060 |
Why?
|
| Neoplasms | 6 | 2011 | 15193 | 0.060 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2003 | 24 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2003 | 99 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2006 | 224 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 639 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 5767 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2023 | 105 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2013 | 1489 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 371 | 0.060 |
Why?
|
| Base Sequence | 3 | 2016 | 4917 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 3981 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2016 | 5270 | 0.060 |
Why?
|
| Cadaver | 1 | 2003 | 237 | 0.060 |
Why?
|
| Oncolytic Virotherapy | 1 | 2006 | 280 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 476 | 0.060 |
Why?
|
| Glucagon | 2 | 1995 | 196 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1996 | 630 | 0.050 |
Why?
|
| Computational Biology | 1 | 2009 | 1271 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2016 | 6089 | 0.050 |
Why?
|
| Perfusion | 1 | 2003 | 293 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2017 | 675 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2013 | 1764 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1363 | 0.050 |
Why?
|
| Observer Variation | 1 | 2023 | 671 | 0.050 |
Why?
|
| Signal Transduction | 4 | 2018 | 11965 | 0.050 |
Why?
|
| Veterans | 1 | 2012 | 1641 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 350 | 0.050 |
Why?
|
| Secretin | 1 | 2021 | 25 | 0.050 |
Why?
|
| Freezing | 1 | 2021 | 59 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 3 | 2007 | 197 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 144 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2021 | 88 | 0.050 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1998 | 19 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2021 | 121 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 5319 | 0.050 |
Why?
|
| Lactoferrin | 1 | 2021 | 81 | 0.050 |
Why?
|
| RNA Stability | 1 | 2021 | 125 | 0.050 |
Why?
|
| Intraoperative Complications | 2 | 2018 | 301 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 7222 | 0.050 |
Why?
|
| Hemorrhage | 2 | 2018 | 712 | 0.050 |
Why?
|
| Canada | 2 | 2011 | 429 | 0.050 |
Why?
|
| Lymphoma, Follicular | 1 | 2005 | 587 | 0.040 |
Why?
|
| Vomiting | 1 | 2001 | 354 | 0.040 |
Why?
|
| Protein Stability | 1 | 2021 | 370 | 0.040 |
Why?
|
| Pemetrexed | 2 | 2010 | 102 | 0.040 |
Why?
|
| Nausea | 1 | 2001 | 525 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 275 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 210 | 0.040 |
Why?
|
| DNA, Neoplasm | 3 | 1998 | 1910 | 0.040 |
Why?
|
| Kinetics | 2 | 2007 | 2049 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 202 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 4367 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 848 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 1375 | 0.040 |
Why?
|
| Prednisone | 1 | 2002 | 984 | 0.040 |
Why?
|
| Syndrome | 1 | 2002 | 1351 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 2231 | 0.040 |
Why?
|
| Proteolysis | 1 | 2021 | 370 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 1998 | 38 | 0.040 |
Why?
|
| Pancreatic Ducts | 2 | 2013 | 122 | 0.040 |
Why?
|
| Endothelial Cells | 4 | 2005 | 1048 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1998 | 149 | 0.040 |
Why?
|
| Pregnancy Trimesters | 1 | 2018 | 36 | 0.040 |
Why?
|
| Bone Density | 1 | 2021 | 476 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3168 | 0.040 |
Why?
|
| Receptors, Glucagon | 1 | 1998 | 36 | 0.040 |
Why?
|
| Gastrinoma | 1 | 1998 | 25 | 0.040 |
Why?
|
| Pathologists | 1 | 2018 | 91 | 0.040 |
Why?
|
| Weight Loss | 2 | 2017 | 627 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 2576 | 0.040 |
Why?
|
| Vincristine | 1 | 2002 | 1511 | 0.040 |
Why?
|
| Genes, p16 | 1 | 1998 | 125 | 0.040 |
Why?
|
| Mice, Inbred ICR | 2 | 2011 | 239 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 38 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2011 | 2292 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1998 | 342 | 0.040 |
Why?
|
| Radiologists | 1 | 2018 | 163 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2013 | 5637 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 83 | 0.040 |
Why?
|
| Cholecystokinin | 1 | 1996 | 45 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 699 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 222 | 0.040 |
Why?
|
| Peptides | 2 | 2007 | 1479 | 0.040 |
Why?
|
| Splenectomy | 1 | 2017 | 158 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1996 | 406 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 7548 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1998 | 347 | 0.030 |
Why?
|
| Liposomes | 2 | 2011 | 684 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5687 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 397 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 160 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.030 |
Why?
|
| Indoles | 2 | 2012 | 1009 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 4314 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2018 | 260 | 0.030 |
Why?
|
| Adolescent | 4 | 2014 | 31252 | 0.030 |
Why?
|
| Pregnancy | 2 | 2018 | 7573 | 0.030 |
Why?
|
| Streptozocin | 1 | 1995 | 75 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 15694 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 3101 | 0.030 |
Why?
|
| Point Mutation | 1 | 1998 | 769 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 155 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1998 | 657 | 0.030 |
Why?
|
| Liver X Receptors | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 3001 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2002 | 3005 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1996 | 423 | 0.030 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 10331 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 643 | 0.030 |
Why?
|
| Rats | 3 | 2011 | 6086 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 216 | 0.030 |
Why?
|
| RNA Interference | 2 | 2009 | 1408 | 0.030 |
Why?
|
| Data Collection | 1 | 2017 | 620 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 85 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 575 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Valosin Containing Protein | 1 | 2013 | 14 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.030 |
Why?
|
| Taxoids | 2 | 2008 | 967 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 1331 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4557 | 0.030 |
Why?
|
| Risk | 2 | 2011 | 1972 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 84 | 0.030 |
Why?
|
| Premature Birth | 1 | 2018 | 407 | 0.030 |
Why?
|
| Models, Animal | 2 | 2007 | 664 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 344 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 795 | 0.030 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2016 | 185 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2013 | 250 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 1546 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 978 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1998 | 1442 | 0.030 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 2390 | 0.030 |
Why?
|
| Fatty Acids | 1 | 1995 | 448 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2011 | 1694 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 2488 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 665 | 0.030 |
Why?
|
| Consent Forms | 1 | 2011 | 25 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| HIV Infections | 1 | 2004 | 2134 | 0.030 |
Why?
|
| Muromonab-CD3 | 1 | 2011 | 19 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 995 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2010 | 1544 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 324 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 6100 | 0.030 |
Why?
|
| Genetic Privacy | 1 | 2011 | 40 | 0.020 |
Why?
|
| Neuroendocrine Tumors | 1 | 1998 | 634 | 0.020 |
Why?
|
| Obesity | 2 | 2017 | 2884 | 0.020 |
Why?
|
| Codon | 1 | 2011 | 241 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 798 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 435 | 0.020 |
Why?
|
| Florida | 1 | 2011 | 113 | 0.020 |
Why?
|
| Heterografts | 1 | 2013 | 733 | 0.020 |
Why?
|
| Smad4 Protein | 1 | 2012 | 196 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 1335 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 409 | 0.020 |
Why?
|
| Phlebography | 1 | 2010 | 76 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 226 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 406 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 67 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 86 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 1054 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2005 | 1385 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2009 | 4804 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2011 | 475 | 0.020 |
Why?
|
| Self Concept | 1 | 2011 | 211 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 5112 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 260 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 437 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 3154 | 0.020 |
Why?
|
| Young Adult | 3 | 2014 | 21445 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 329 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 462 | 0.020 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2009 | 32 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1959 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 677 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2009 | 78 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2011 | 310 | 0.020 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2009 | 53 | 0.020 |
Why?
|
| Thymidylate Synthase | 1 | 2009 | 53 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2009 | 198 | 0.020 |
Why?
|
| Public Health | 1 | 2011 | 299 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2006 | 3536 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2010 | 250 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2009 | 117 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 6942 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2011 | 319 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.020 |
Why?
|
| Cell Line | 1 | 1996 | 5114 | 0.020 |
Why?
|
| Cobalt | 1 | 2008 | 55 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4143 | 0.020 |
Why?
|
| Health Status | 1 | 2011 | 590 | 0.020 |
Why?
|
| Pyrroles | 1 | 2012 | 576 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 200 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 4844 | 0.020 |
Why?
|
| Eating | 1 | 1990 | 421 | 0.020 |
Why?
|
| Proinsulin | 1 | 2007 | 23 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 324 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 823 | 0.020 |
Why?
|
| Venoms | 1 | 2007 | 23 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 760 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2003 | 16273 | 0.020 |
Why?
|
| Virion | 1 | 2008 | 161 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 328 | 0.020 |
Why?
|
| Estramustine | 1 | 2006 | 26 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 211 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 938 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 2314 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 1062 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 541 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 870 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 6682 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 1549 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 287 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 191 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2007 | 240 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2006 | 135 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 524 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2005 | 40 | 0.020 |
Why?
|
| Vinblastine | 1 | 2006 | 453 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 259 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 1290 | 0.020 |
Why?
|
| Receptors, Neuropeptide | 1 | 2005 | 27 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2005 | 89 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8223 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 1123 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 862 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 257 | 0.020 |
Why?
|
| Bisexuality | 1 | 2004 | 17 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 280 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 1996 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2004 | 21 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2008 | 837 | 0.020 |
Why?
|
| Umbilical Cord | 1 | 2004 | 54 | 0.020 |
Why?
|
| ras Proteins | 1 | 2009 | 770 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2006 | 250 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 2045 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 866 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 211 | 0.020 |
Why?
|
| Flucytosine | 1 | 2004 | 30 | 0.020 |
Why?
|
| Protein Folding | 1 | 2005 | 281 | 0.010 |
Why?
|
| Lac Operon | 1 | 2004 | 122 | 0.010 |
Why?
|
| Simplexvirus | 1 | 2004 | 159 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2004 | 69 | 0.010 |
Why?
|
| Epilepsy | 1 | 2011 | 883 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2006 | 478 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 397 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 255 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 1216 | 0.010 |
Why?
|
| Genome, Human | 1 | 2011 | 1869 | 0.010 |
Why?
|
| Quinazolines | 1 | 2008 | 923 | 0.010 |
Why?
|
| Dogs | 1 | 2005 | 1155 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2011 | 1589 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 317 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 750 | 0.010 |
Why?
|
| Virus Replication | 1 | 2006 | 709 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2063 | 0.010 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 716 | 0.010 |
Why?
|
| Remission Induction | 1 | 2009 | 3569 | 0.010 |
Why?
|
| Child | 1 | 2003 | 29154 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 598 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4053 | 0.010 |
Why?
|
| Smoking | 1 | 2011 | 2440 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 716 | 0.010 |
Why?
|
| Cisplatin | 1 | 2008 | 2432 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 703 | 0.010 |
Why?
|
| Mental Health | 1 | 2004 | 415 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2009 | 2054 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2003 | 703 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3552 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 2316 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3251 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2008 | 1471 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2008 | 1823 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 1282 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5539 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 1099 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 4078 | 0.010 |
Why?
|
| Progesterone | 1 | 1998 | 513 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6009 | 0.010 |
Why?
|
| CpG Islands | 1 | 1998 | 633 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 4758 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5178 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 6295 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 2961 | 0.010 |
Why?
|
| Testosterone | 1 | 1998 | 619 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 5437 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 10035 | 0.010 |
Why?
|
| DNA Methylation | 1 | 1998 | 2669 | 0.000 |
Why?
|
| Lymphangiosarcoma | 1 | 1951 | 1 | 0.000 |
Why?
|
| Lymphatic System | 1 | 1951 | 64 | 0.000 |
Why?
|
| Lymphangioma | 1 | 1951 | 36 | 0.000 |
Why?
|
| Lymphedema | 1 | 1951 | 239 | 0.000 |
Why?
|
| Mastectomy | 1 | 1951 | 1534 | 0.000 |
Why?
|
| Breast | 1 | 1951 | 1344 | 0.000 |
Why?
|